Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

26 citing papers in PubMed, 32 citations in OpenAlex.

1. Protein modification systems as cancer biomarkers and therapeutic targets.Precision clinical medicine · 2026
   Review
2. If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.Med (New York, N.Y.) · 2025
   Review
3. Loss of Heterozygosity and Mutations in the RAS-ERK Pathway Genes in Tumor Cells of Various Loci in Multiple Myeloma.International journal of molecular sciences · 2024
   Article
4. DNA Sequencing of CD138 Cell Population Reveals TP53 and RAS-MAPK Mutations in Multiple Myeloma at Diagnosis.Cancers · 2024
   Article
5. Targeted therapy for multiple myeloma: an overview on CD138-based strategies.Frontiers in oncology · 2024
   Review
6. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFESMO open · 2023
   Article
7. Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study.Cancers · 2023
   Article
8. Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma.International journal of molecular sciences · 2023
   Review
9. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma.Blood advances · 2022
   Article
10. Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup.Life (Basel, Switzerland) · 2022
    Review
11. Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance.BMJ case reports · 2022
    Article
12. KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders.Cancers · 2022
    Review
13. Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism inClinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
14. Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article.Cancers · 2021
    Review
15. José Baselga M.D., Ph.D. (1959-2021) leading cancer researcher and oncologist.Journal of experimental & clinical cancer research : CR · 2021
    Article
16. MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age.Cold Spring Harbor perspectives in medicine · 2021
    Review
17. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.Drugs · 2021
    Review
18. Juniperus indica Bertol. extract synergized with cisplatin against melanoma cells via the suppression of AKT/mTOR and MAPK signaling and induction of cell apoptosis.International journal of medical sciences · 2021
    Article
19. Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams.Frontiers in oncology · 2021
    Review
20. Novel Experimental Drugs for Treatment of Multiple Myeloma.Journal of experimental pharmacology · 2021
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

18 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.